Indapamide Market
Indapamide Market Size, Share & Trends Analysis by Product Type (Immediate-Release Tablets, Sustained/Extended-Release Tablets), by Strength (1.25 mg, 2.5 mg, Other Customized Dosages), by Application (Hypertension, Edema, Heart Failure), Forecast Period (2026-2035)
Industry Overview
Indapamide market was valued at $110.4 million in 2025 and is projected to reach $142.4 million by 2035, growing at a CAGR of 2.6% from 2026 to 2035. The global indapamide market is supported primarily by continued demand for antihypertensive therapy and the established use of indapamide as a thiazide-like diuretic. The market remains strongly generic in structure, with manufacturers supplying immediate-release and modified- or sustained-release formulations across multiple healthcare systems. Combination products containing indapamide with agents such as perindopril or amlodipine also contribute to product diversification. Regulatory listings across North America, Europe, and Asia demonstrate continued availability of indapamide products. Pharmaceutical companies are also maintaining API and finished-dose manufacturing capabilities to serve regulated and emerging markets. Increasing emphasis on long-term blood-pressure management and generic substitution continues to underpin demand.
Market Dynamics
Modified-Release Indapamide Formulations
Modified-release formulations represent an important trend as manufacturers continue to supply indapamide in formulations designed for prolonged drug release. The 1.5 mg sustained- or prolonged-release format is established across European and other international markets, with products from several generic manufacturers listed by national medicine authorities. This formulation approach supports once-daily treatment and has become an important part of the generic product landscape. Current regulatory information continues to identify prolonged-release indapamide products as active medicines. The presence of multiple manufacturers also encourages continued competition in this formulation segment.
Combination Antihypertensive Products
Combination therapy remains another significant market trend because indapamide can be incorporated into antihypertensive products containing complementary active ingredients. Servier's portfolio, for example, includes indapamide in combination with amlodipine and in a triple combination with perindopril and amlodipine. Such formulations allow manufacturers to address treatment regimens involving multiple mechanisms within a single dosage form. Regulatory databases in different countries continue to document indapamide-containing combinations. Generic manufacturers are also active in this category, creating a broad competitive environment around established combination formulations.
Market Segmentation
- Based on the product type, the market is segmented into immediate-release (IR) tablets and sustained/extended-release (SR/ER) tablets.
- Based on the strength, the market is segmented into 1.25 mg, 2.5 mg, and other customized dosages.
- Based on the application, the market is segmented into hypertension, edema, and heart failure.
Sustained-Release Tablets Segment to Lead the Market with the Largest Share
Sustained-release tablets constitute an important product segment because the 1.5 mg modified-release formulation has substantial regulatory and commercial presence across European and international markets. Current national medicine databases continue to list prolonged-release indapamide products from multiple manufacturers, indicating continued market availability. The formulation is particularly relevant to once-daily hypertension treatment and has become a standard part of the generic indapamide product portfolio.
Combination Therapy: A Key Segment in Market Growth
Combination therapy is a significant application-oriented subsegment because indapamide is commercially incorporated with other antihypertensive agents, including perindopril and amlodipine. Such products are available from both originator-associated and generic manufacturers and provide an additional route for pharmaceutical companies to differentiate their indapamide portfolios. Current regulatory records continue to document indapamide-containing combination products.
Regional Outlook
The global indapamide market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
Europe Region Dominates the Market with Major Share
Europe remains a major region for the indapamide market because the medicine has a long-established presence in national healthcare systems and generic-drug frameworks. Regulatory databases across European countries list multiple indapamide products, including prolonged-release formulations and combination therapies. The region also has established pharmaceutical manufacturers and generic suppliers with experience in cardiovascular medicines. Continued availability of both originator-associated and generic products supports a diversified supply structure. National reimbursement systems and established hypertension-management practices further sustain demand for established antihypertensive medicines.
Asia-Pacific to Witness as a Fastest Growing Region
Asia-Pacific is positioned as a key growth region as hypertension treatment expands alongside broader access to generic medicines and pharmaceutical manufacturing capacity. India in particular has a substantial network of pharmaceutical manufacturers and exporters involved in indapamide supply, while China and other Asian markets contribute API and pharmaceutical manufacturing capabilities. Current trade information identifies Indian companies supplying indapamide internationally, while company portfolios demonstrate continued availability of indapamide formulations. Expansion of affordable generic treatment and increasing cardiovascular-disease management requirements provide structural support for regional demand.
Market Players Outlook
The major companies operating in the global indapamide market include Servier, Teva Pharmaceuticals, Viatris, KRKA, and Torrent Pharmaceuticals Limited, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In January 2025, Taj Pharmaceuticals Limited launched Tablets 2.5 mg, describing the product as indapamide tablets IP in film-coated tablet form and positioning it within its diuretic portfolio. The company provides technical and regulatory documentation for the product, including manufacturing and quality-related information.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global indapamide market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Indapamide Market Sales Analysis – Product Type | Strength | Application ($ Million)
- Indapamide Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Indapamide Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Indapamide Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Indapamide Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Indapamide Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Indapamide Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Indapamide Market Revenue and Share by Manufacturers
- Indapamide Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- KRKA
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Servier
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Teva Pharmaceuticals
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Torrent Pharmaceuticals Limited
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Viatris
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- KRKA
- Key Company Analysis
- Global Indapamide Market Sales Analysis by Product Type ($ Million)
- Immediate-Release (IR) Tablets
- Sustained/Extended-Release (SR/ER) Tablets
- Global Indapamide Market Sales Analysis by Strength ($ Million)
- 25 mg
- 5 mg
- Other Customized Dosages
- Global Indapamide Market Sales Analysis by Application ($ Million)
- Hypertension
- Edema (Fluid Retention)
- Heart Failure (Adjunct Therapy)
- Regional Analysis
- North American Indapamide Market Sales Analysis – Product Type | Strength | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Indapamide Market Sales Analysis – Product Type | Strength | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Indapamide Market Sales Analysis – Product Type | Strength | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Others)
- Rest of Asia-Pacific
- Rest of the World Indapamide Market Sales Analysis – Product Type | Strength | Application | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Ami Lifesciences Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bioindustria L.I.M. S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CHEMO
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cohance Lifesciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Delta Finochem Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Guangzhou Tosun Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Industriale Chimica S.r.l.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipca Laboratories Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- JAMP Pharma Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiwan Pharmaceutical Technology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- KRKA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Medigraph Pharmaceuticals Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Octavius Pharma Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Osmopharm
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Quimica Sintetica
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Recipharm AB
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Refarmed Chemicals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Servier
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Supra Chemicals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Suzhou Bichal Biological Technology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Suzhou Lixin Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Taj Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Torrent Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ami Lifesciences Private Limited
1. Global Indapamide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Global Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Indapamide Market Research and Analysis by Strength, 2025–2035 ($ Million)
5. Global 1.25 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global 2.5 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Indapamide Market Research and Analysis by Application, 2025–2035 ($ Million)
9. Global Indapamide for Hypertension Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Indapamide for Edema (Fluid Retention) Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Indapamide for Heart Failure (Adjunct Therapy) Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Indapamide Market Research And Analysis By Geography, 2025-2035 ($ Million)
13. North American Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
14. North American Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
15. North American Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
16. North American Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
17. European Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
18. European Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
19. European Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
20. European Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
21. Asia-Pacific Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
22. Asia-Pacific Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
23. Asia-Pacific Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
24. Asia-Pacific Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
25. Rest Of The World Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
26. Rest Of The World Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
27. Rest Of The World Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
28. Rest Of The World Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
1. Global Indapamide Market Share by Product Type, 2025 vs 2035 (%)
2. Global Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Indapamide Market Share by Strength, 2025 vs 2035 (%)
5. Global 1.25 mg Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Global 2.5 mg Indapamide Market Research and Analysis by Region, 2025 vs 2035 (%)
7. Global Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. Global Indapamide Market Share by Application, 2025 vs 2035 (%)
9. Global Indapamide for Hypertension Market Research and Analysis by Region, 2025 vs 2035 (%)
10. Global Indapamide for Edema (Fluid Retention) Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Global Indapamide for Heart Failure (Adjunct Therapy) Market Research and Analysis by Region, 2025 Vs 2035 (%)
12. Global Indapamide Market Share By Region, 2025 Vs 2035 (%)
13. US Indapamide Market Size, 2025-2035 ($ Million)
14. Canada Indapamide Market Size, 2025-2035 ($ Million)
15. UK Indapamide Market Size, 2025-2035 ($ Million)
16. France Indapamide Market Size, 2025-2035 ($ Million)
17. Germany Indapamide Market Size, 2025-2035 ($ Million)
18. Italy Indapamide Market Size, 2025-2035 ($ Million)
19. Spain Indapamide Market Size, 2025-2035 ($ Million)
20. Russia Indapamide Market Size, 2025-2035 ($ Million)
21. Rest Of Europe Indapamide Market Size, 2025-2035 ($ Million)
22. India Indapamide Market Size, 2025-2035 ($ Million)
23. China Indapamide Market Size, 2025-2035 ($ Million)
24. Japan Indapamide Market Size, 2025-2035 ($ Million)
25. South Korea Indapamide Market Size, 2025-2035 ($ Million)
26. ASEAN Indapamide Market Size, 2025-2035 ($ Million)
27. Australia and New Zealand Indapamide Market Size, 2025-2035 ($ Million)
28. Rest Of Asia-Pacific Indapamide Market Size, 2025-2035 ($ Million)
29. Latin America Indapamide Market Size, 2025-2035 ($ Million)
30. Middle East And Africa Indapamide Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
